Bengaluru-based startup NeoDx Biotech Labs has expanded its portfolio with the BCR-ABL range of  Real-Time PCR detection kit, an in-vitro diagnostic test for aiding in the diagnosis of chronic myelogenous leukaemia (CML).

 

BCR-ABL1 translocation is detected in 90-95% of CML cases. Detection of the BCR-ABL translocation not only aids the initial diagnosis of CML but is also useful for monitoring tyrosine kinase inhibitor response status and monitoring minimal residual disease (MRD).

NeoDx’s BCR-ABL Qualitative and Quantitative is a one-step (no additional cDNA conversion of RNA is required), multiplex (Major, Minor,  and Micro transcripts) format along with ABL amplification in a single tube.

Quantitative kits were standardised using World Health Organisation (WHO) reference standards, where the deep molecular response up to 4.5 log reduction can be analysed. The assay run time for both qualitative and quantitative is under 90 minutes.

While developing the kit was a challenge, NeoDx’s team of scientists wanted to design a product that would help healthcare professionals better understand their patient’s prognosis; thereby supporting the overall treatment outcomes for the patients.

BCR ABL Quantitative kit identifies over 14 BCR-ABL major transcripts making it one of the most unique indigenously developed kits.